About Skyhawk Therapeutics
Skyhawk Therapeutics is a company based in Waltham (United States) founded in 2017.. Skyhawk Therapeutics has raised $181 million across 3 funding rounds from investors including Fidelity Investments, ARE and Disney. Skyhawk Therapeutics operates in a competitive market with competitors including Enliven Therapeutics, Nuvalent, Nura Bio, Abbisko Therapeutics and NewAmsterdam Pharma, among others.
- Headquarter Waltham, United States
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$181 M (USD)
in 3 rounds
-
Latest Funding Round
$133 M (USD), Series B
Sep 14, 2021
-
Investors
Fidelity Investments
& 7 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Funding Insights of Skyhawk Therapeutics
Skyhawk Therapeutics has successfully raised a total of $181M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $133 million completed in September 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series B — $133.0M
-
First Round
First Round
(23 Jan 2018)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2021 | Amount | Series B - Skyhawk Therapeutics | Valuation | Fidelity Investments |
|
| Jun, 2018 | Amount | Series A - Skyhawk Therapeutics | Valuation | Agent Capital , Alexandria |
|
| Jan, 2018 | Amount | Seed - Skyhawk Therapeutics | Valuation | Disney , Alexandria |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Skyhawk Therapeutics
Skyhawk Therapeutics has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, ARE and Disney. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Agent Capital is focused on healthcare venture capital investments.
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on early-stage big data, health tech, AI, food tech, and multiple sectors
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Skyhawk Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Skyhawk Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Skyhawk Therapeutics Comparisons
Competitors of Skyhawk Therapeutics
Skyhawk Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Enliven Therapeutics, Nuvalent, Nura Bio, Abbisko Therapeutics and NewAmsterdam Pharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of drugs for solid tumours and blood cancers
|
|
| domain | founded_year | HQ Location |
Therapeutic solutions for cancer, including NSCLC inhibitors, are developed.
|
|
| domain | founded_year | HQ Location |
Diagnostic solutions and neuroprotective medicines for neurological disorders are provided.
|
|
| domain | founded_year | HQ Location |
Developing novel small molecule drugs for immunomodulatory pathways to treat cancer
|
|
| domain | founded_year | HQ Location |
Therapeutic solutions for cardio-metabolic diseases are developed using obicetrapib.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Skyhawk Therapeutics
Frequently Asked Questions about Skyhawk Therapeutics
When was Skyhawk Therapeutics founded?
Skyhawk Therapeutics was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Where is Skyhawk Therapeutics located?
Skyhawk Therapeutics is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Is Skyhawk Therapeutics a funded company?
Skyhawk Therapeutics is a funded company, having raised a total of $181M across 3 funding rounds to date. The company's 1st funding round was a Seed of $8M, raised on Jan 23, 2018.
What does Skyhawk Therapeutics do?
Founded in 2017 and based in Waltham, United States, small molecules that modify RNA are discovered by Skyhawk Therapeutics for applications in neurodegenerative, oncology, neuromuscular, rare, and other diseases. Proprietary structural, kinetic, and computational models are utilized to identify these candidates. Operations focus on advancing therapies across various therapeutic areas within the biotechnology sector.
Who are the top competitors of Skyhawk Therapeutics?
Skyhawk Therapeutics's top competitors include Nuvalent, Enliven Therapeutics and Abbisko Therapeutics.
Who are Skyhawk Therapeutics's investors?
Skyhawk Therapeutics has 8 investors. Key investors include Fidelity Investments, ARE, Disney, Good Growth Capital, and Agent Capital.